Literature DB >> 21049830

Enhancing adherence through education.

Jennifer Smrtka1, Christina Caon, Carol Saunders, Brenda L Becker, Nancy Baxter.   

Abstract

The treatment of multiple sclerosis (MS) has advanced greatly since the introduction of disease-modifying therapies (DMTs) in the early 1990s. Although the DMTs have exhibited significant efficacy in relapsing-remitting MS and other forms of the disease, the degree of benefit depends heavily on patient adherence to recommended regimens. This article addresses some of the most pressing areas of unmet need in educating advanced-practice nurses, neurologists, patients, and support care partners regarding strategies that can overcome obstacles to adherence. The observations presented here are based on clinical experience with real-life cognitive, psychosocial, and cultural impediments to adherence. The article also explores the ways in which adherence may be affected by emerging therapies for MS (such as oral agents) as well as the educational needs that will arise with the further evolution of MS care.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21049830     DOI: 10.1097/jnn.0b013e3181ef82b6

Source DB:  PubMed          Journal:  J Neurosci Nurs        ISSN: 0888-0395            Impact factor:   1.230


  6 in total

1.  Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis.

Authors:  Rachel Halpern; Sonalee Agarwal; Carole Dembek; Leigh Borton; Maria Lopez-Bresnahan
Journal:  Patient Prefer Adherence       Date:  2011-01-20       Impact factor: 2.711

2.  Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program.

Authors:  Zaza Katsarava; Birgit Ehlken; Volker Limmroth; Kirsi Taipale; Sarita Noemi Patel; Gabriele Niemczyk; Karin Rehberg-Weber; Colin Wernsdörfer
Journal:  BMC Neurol       Date:  2015-09-22       Impact factor: 2.474

3.  Knowledge and attitude assessment of Iranian multiple sclerosis patients receiving interferon beta.

Authors:  Roya Abolfazli; Azam Elyasi; Mohammad Reza Javadi; Kheirollah Gholami; Hassan Torkamandi; Mohammad Amir-Shahkarami; Masoud Etemadifar; Zahra Nasr
Journal:  Iran J Neurol       Date:  2014-07-04

4.  The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences.

Authors:  Cynthia Plunkett; Ariel L Barkan
Journal:  Patient Prefer Adherence       Date:  2015-07-30       Impact factor: 2.711

5.  Treatment adherence in multiple sclerosis: a survey of Belgian neurologists.

Authors:  Danny Decoo; Mathieu Vokaer
Journal:  Patient Prefer Adherence       Date:  2015-11-19       Impact factor: 2.711

6.  Comparative evaluation of patients' and physicians' satisfaction with interferon beta-1b therapy.

Authors:  Uwe Klaus Zettl; Ulrike Bauer-Steinhusen; Thomas Glaser; Klaus Hechenbichler; Michael Hecker
Journal:  BMC Neurol       Date:  2016-09-21       Impact factor: 2.474

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.